An Open-Label Study To Evaluate The Safety and Tolerability Of A Novel LPA1 Receptor Positron Emission Tomography (PET) Ligand [11C]BMT-136088 And To Assess Receptor Occupancy In Human Lung Following Oral Administration Of BMS-986020 In Healthy Subjects

Trial Profile

An Open-Label Study To Evaluate The Safety and Tolerability Of A Novel LPA1 Receptor Positron Emission Tomography (PET) Ligand [11C]BMT-136088 And To Assess Receptor Occupancy In Human Lung Following Oral Administration Of BMS-986020 In Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Apr 2015

At a glance

  • Drugs BMS 986020 (Primary) ; Carbon-11-BMT 136088 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Pharmacodynamics
  • Sponsors Bristol-Myers Squibb
  • Most Recent Events

    • 24 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 27 Jan 2015 Status changed from recruiting to active, no longer recruiting, according to CliniclTrials.gov record.
    • 20 Nov 2014 According to the ClinicalTrials.gov record, planned end date changed from 1 Nov 2014 to 1 Feb 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top